Golotimod
Also known as: gamma-D-glutamyl-L-tryptophan, Glu-Trp, SCV-07
Source Golotimod at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Golotimod (SCV-07) is a synthetic dipeptide immunomodulator derived from gamma-D-glutamyl-L-tryptophan. It has been investigated for treatment of tuberculosis, hepatitis C, and other infectious diseases as an immune adjunct therapy. It aims to restore or enhance cell-mediated immunity, particularly in immunocompromised patients.
Mechanism of Action
Toll-like receptor 9 (TLR9) agonist and immunomodulator; stimulates T-cell maturation and differentiation, enhances innate and adaptive immune responses by activating dendritic cells and promoting Th1-type cytokine production
Routes of Administration
Goals & Uses
- Adjunct treatment of tuberculosisInfectious DiseaseModerate
- Oral mucositis preventionOncology Supportive CareLow
- Immune restoration in immunocompromised patientsImmunologyLow
- Hepatitis C treatment supportInfectious DiseaseLow
Contraindications
- Autoimmune conditions (active)AutoimmuneModerate
- Known hypersensitivity to golotimod or componentsAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- Gastrointestinal discomfortGastrointestinalUncommon
- FatigueGeneralUncommonLow energy or tiredness
- FeverSystemicUncommonElevated body temperature
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
- Antitubercular agents (e.g., rifampicin, isoniazid)Low
Population Constraints
- Severe renal or hepatic impairmentOrgan FunctionRelative
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
Regulatory Status
- European UnionInvestigationalNo EMA approval; clinical trials conducted in Eastern Europe and Russia
- United StatesInvestigationalInvestigated under IND; not FDA approved for any indication
- United KingdomUnknownNo known MHRA approval; status not clearly defined
Not approved by FDA, EMA, or other major regulatory agencies. Studied under investigational new drug (IND) status in clinical trials. Developed by SciClone Pharmaceuticals and related entities.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Golotimod?
Golotimod (SCV-07) is a synthetic dipeptide immunomodulator derived from gamma-D-glutamyl-L-tryptophan. It has been investigated for treatment of tuberculosis, hepatitis C, and other infectious diseases as an immune adjunct therapy. It aims to restore or enhance cell-mediated immunity, particularly in immunocompromised patients.
What is Golotimod used for?
Golotimod is educationally associated with: Adjunct treatment of tuberculosis, Oral mucositis prevention, Immune restoration in immunocompromised patients, Hepatitis C treatment support. Educational only — not medical advice.
How is Golotimod administered?
Recorded routes of administration: Oral, Subcutaneous.
What are the potential side effects of Golotimod?
Reported adverse effects include: Injection site reactions, Gastrointestinal discomfort, Fatigue, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid Golotimod?
Recorded contraindications: Autoimmune conditions (active), Known hypersensitivity to golotimod or components. Consult a qualified clinician before use.